Bio-Techne Corporation (TECH)
- Previous Close
62.66 - Open
62.72 - Bid 64.04 x 100
- Ask 64.19 x 400
- Day's Range
62.49 - 64.36 - 52 Week Range
51.79 - 89.91 - Volume
946,213 - Avg. Volume
1,093,892 - Market Cap (intraday)
10.07B - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
46.09 - EPS (TTM)
1.39 - Earnings Date May 1, 2024
- Forward Dividend & Yield 0.32 (0.50%)
- Ex-Dividend Date Feb 9, 2024
- 1y Target Est
80.55
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
www.bio-techne.comRecent News: TECH
Performance Overview: TECH
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TECH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TECH
Valuation Measures
Market Cap
10.07B
Enterprise Value
10.49B
Trailing P/E
46.09
Forward P/E
32.36
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.03
Price/Book (mrq)
5.13
Enterprise Value/Revenue
9.16
Enterprise Value/EBITDA
27.90
Financial Highlights
Profitability and Income Statement
Profit Margin
19.58%
Return on Assets (ttm)
6.32%
Return on Equity (ttm)
11.83%
Revenue (ttm)
1.14B
Net Income Avi to Common (ttm)
224.11M
Diluted EPS (ttm)
1.39
Balance Sheet and Cash Flow
Total Cash (mrq)
135.65M
Total Debt/Equity (mrq)
28.30%
Levered Free Cash Flow (ttm)
162.75M
Research Analysis: TECH
Company Insights: TECH
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: TECH
The Argus Mid-Cap Model Portfolio
Small- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.
Analyst Report: Bio-Techne Corp
Based in Minneapolis, Bio-Techne develops and markets protein-based instruments and reagents for research and clinical use. Its customers include companies in the pharmaceutical and biotech industries as well as academic research institutions. The company's products and solutions aid in drug discovery and provide the means for accurate clinical tests and diagnoses. Through its Protein Sciences business segment, Bio-Techne is one of the world's leading suppliers of proteins, such as cytokines and growth factors, immunoassays, antibodies, and reagents to the biotech and academic research communities. Bio-Techne's Diagnostics and Genomics segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays, and other bulk and custom reagents for the in-vitro diagnostic market.
RatingPrice TargetMarket Digest: TECH, HPE
A New Year Ahead: Our Monthly Survey of the Economy, Interest Rates, and Stocks
Weekly Stock List
Here is the list of the Top Picks for 2024 from the Argus team of analysts. The team is deeply experienced, as each analyst has spent ,on average, 25 years on Wall Street and 15 years at Argus Research. As such, our analysts are extremely well-versed in our proprietary fundamental six-point system and the sectors they cover. They also have solid relationships with many of the management teams they cover. But they do not operate in a vacuum. An Investment Policy Committee (IPC) comprised of Director of Research Jim Kelleher, CFA; President John Eade; Chief Compliance Officer & Senior Financial Analyst Kevin Heal; and Director of Financial Institutions Research Steve Biggar provide macro outlooks for the economy, interest rates, earnings, and the stock market. The IPC reviews all proposed ratings changes. Our list below is organized by sector.